Melanoma Diagnostics And Therapeutics
Melanoma Diagnostics and Therapeutics Market Forecasts to 2030 - Global Analysis By Cancer Type (Acral Lentiginous Melanoma, Amelanotic Melanoma and Other Cancer Types), By Diagnosis (Dermatoscopy, Blood Tests, Computed Tomography (CT) Scan and Other Diagnosis), Therapy, Application and By Geography
|
Years Covered |
2021-2030 |
|
CAGR (2023-2030) |
17.1% |
|
Regions Covered |
North America, Europe, Asia Pacific, South America, and Middle East & Africa |
|
Countries Covered |
US, Canada, Mexico, Germany, UK, Italy, France, Spain, Japan, China, India, Australia, New Zealand, South Korea, Rest of Asia Pacific, South America, Argentina, Brazil, Chile, Middle East & Africa, Saudi Arabia, UAE, Qatar, and South Africa |
|
Largest Market |
North America |
|
Highest Growing Market |
Asia Pacific |
According to Stratistics MRC, the Global Melanoma Diagnostics and Therapeutics Market is growing at a CAGR of 17.1% during the forecast period. Melanoma diagnostics involve the identification and assessment of melanocytic lesions to diagnose skin cancer. Techniques include dermoscopy, biopsy, and molecular testing to analyze genetic mutations. Therapeutics for melanoma comprise surgical excision, immunotherapy, targeted therapy, and chemotherapy. Immunotherapies like checkpoint inhibitors and targeted therapies addressing specific genetic alterations play a crucial role. Early detection and personalized treatment strategies are pivotal in managing melanoma.
According to the American Cancer Society, about 99,780 new melanomas will be diagnosed in the United States in 2022, and around 7,650 people are expected to die of melanoma in the same year.
Market Dynamics:
Driver:
Rising incidence of melanoma
Factors such as prolonged sun exposure, changing lifestyles, and genetic predispositions contribute to a rising number of melanoma cases globally. This surge in incidence necessitates advanced diagnostic tools and therapeutic interventions. Increased awareness campaigns and routine skin screenings further amplify the demand for early detection and effective treatments. The industry's response to this growing health concern involves continuous innovation in diagnostics and therapeutics, positioning the rising incidence of melanoma as a crucial driver fueling market expansion.
Restraint:
High treatment costs
The expenses associated with innovative diagnostics, targeted therapies, and immunotherapies for melanoma can be substantial, limiting accessibility for a portion of the patient population. This financial barrier hampers timely and optimal treatment, potentially impacting patient outcomes. Additionally, high costs may strain healthcare systems and result in economic challenges for both individuals and payers, impacting overall market growth.
Opportunity:
Advancements in diagnostic technologies
Innovative diagnostic tools, such as high-resolution imaging techniques, liquid biopsy assays, and molecular profiling, enable earlier and more accurate detection of melanoma. The enhanced sensitivity and specificity of these technologies contribute to timely interventions, improving patient outcomes. Moreover, non-invasive and precise diagnostic methods align with the growing trend of personalized medicine, facilitating tailored treatment approaches. These technological advancements not only aid in early diagnosis but also play a crucial role in monitoring treatment response and disease progression.
Threat:
Limited availability of specialized healthcare centers
The limited availability of specialized healthcare centers represents a significant threat to the melanoma diagnostics and therapeutics market. Melanoma often requires specialized expertise for accurate diagnosis and tailored treatment plans. The scarcity of such centers can lead to delays in diagnosis, hinder access to advanced therapeutic interventions, and limit patient outcomes. Additionally, patients may face geographical barriers, particularly in underserved regions, impacting timely access to crucial diagnostic services and cutting-edge therapies, which limits market expansion.
Covid-19 Impact:
The COVID-19 pandemic significantly impacted the melanoma diagnostics and therapeutics market. Disruptions in healthcare services, reprioritization of resources, and patients' concerns about visiting healthcare facilities led to delays in melanoma diagnosis and treatment. However, the pandemic underscored the importance of innovative and remote healthcare solutions, accelerating the adoption of telemedicine and digital health technologies.
The blood tests segment is expected to be the largest during the forecast period
The blood testing segment is expected to be the largest in the melanoma diagnostics market due to its non-invasive nature and efficiency in detecting biomarkers associated with melanoma. Blood-based tests offer a convenient and accessible means for early detection, enabling timely intervention. Advancements in liquid biopsy technologies and the identification of circulating tumor markers in blood contribute to the segment's prominence. As the demand for accurate, less invasive diagnostic methods grows, the blood testing segment is anticipated to dominate, catering to the increasing need for effective melanoma detection and monitoring.
The radiotherapy segment is expected to have the highest CAGR during the forecast period
The radiotherapy segment is projected to achieve lucrative growth in the melanoma diagnostics and therapeutics market. This growth is attributed to the increasing adoption of radiotherapy as an effective treatment option for melanoma. Technological advancements in radiotherapy techniques, including intensity-modulated radiation therapy (IMRT) and stereotactic radiosurgery, contribute to enhanced precision and reduced side effects. The growing emphasis on combination therapies, where radiotherapy is integrated into comprehensive treatment strategies, further propels the demand for radiotherapy.
Region with largest share:
North America is poised to command the largest market share in the melanoma diagnostics and therapeutics market due to its advanced healthcare infrastructure, a high prevalence of melanoma cases, and robust research and development activities. Moreover, increasing awareness, early adoption of innovative diagnostic technologies, and the presence of key market players contribute to North America's dominant position. Additionally, favorable reimbursement policies, a proactive regulatory environment, and a focus on personalized medicine further drive the region's leadership in the market.
Region with highest CAGR:
The Asia Pacific region is poised to experience the highest growth rate in the melanoma diagnostics and therapeutics market due to increasing awareness, improving healthcare infrastructure, rising disposable income, and a growing aging population that contribute to a higher prevalence of melanoma cases. Additionally, advancements in healthcare technologies, expanding research initiatives, and a focus on personalized medicine in key economies within the region further drive the demand for advanced diagnostics and therapeutics.
Key players in the market
Some of the key players in Melanoma Diagnostics And Therapeutics Market include Abbott Diagnostics, Agilent Technologies, Amgen, Inc., AstraZeneca, Biomérieux SA, Bristol Myers Squibb, Caliber Imaging & Diagnostics, Inc., Canfield Scientific, Inc., Dermlite, DermTech, Eli Lilly and Company, Roche Holding AG, GlaxoSmithKline PLC, Merck & Co., Inc, Novartis AG, Pfizer, Inc., Qiagen and Sanofi.
Key Developments:
In November 2023, The U.S. Food and Drug Administration (FDA) approved Eli Lilly and Company's Zepbound™ (tirzepatide) injection, the first and only obesity treatment of its kind that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors.
In November 2023, Amgen announced new data reinforcing the safety and efficacy of Repatha® (evolocumab) from the FOURIER Open Label Extension (OLE) [FOURIER-OLE] trial at the American Heart Association (AHA) Scientific Sessions 2023 in Philadelphia. These presentations will focus on the reduction of a known cardiovascular disease (CVD) risk factor, LDL ""bad"" cholesterol (LDL-C). Amgen will also present new research from the Phase 2 OCEAN(a)-DOSE study of its investigational small interfering RNA (siRNA) olpasiran that will focus on a primarily genetically determined and presumed independent CVD risk factor, lipoprotein(a) [Lp(a)].
In October 2023, Novartis, a global leader in immuno-dermatology and rheumatology, announced that the US Food and Drug Administration (FDA) has approved Cosentyx® (secukinumab) to treat moderate to severe hidradenitis suppurativa (HS) in adults. Cosentyx is the only FDA-approved fully human biologic that directly inhibits interleukin-17A (IL-17A), a cytokine believed to be involved in the inflammation of HS.
Cancer Types Covered:
• Acral Lentiginous Melanoma
• Amelanotic Melanoma
• Lentigno gna Melanoma
• Nodular Melanoma
• Superficial Spreading Melanoma
• Other Cancer Types
Diagnosis Covered:
• Dermatoscopy
• Blood Tests
• Computed Tomography (CT) Scan
• Sentinel Lymph Node Biopsy
• Ultrasound
• X-Rays
• Other Diagnosis
Therapies Covered:
• Chemotherapy
• Biological Therapy
• Immune Therapy
• Radiotherapy
• Targeted Therapy
• Other Therapies
Applications Covered:
• Diagnostic Centers
• Hospitals
• Medical Institutions
• Other Applications
Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o South Korea
o Rest of Asia Pacific
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
Table of Contents
1 Executive Summary
2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Application Analysis
3.7 Emerging Markets
3.8 Impact of Covid-19
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Melanoma Diagnostics and Therapeutics Market, By Cancer Type
5.1 Introduction
5.2 Acral Lentiginous Melanoma
5.3 Amelanotic Melanoma
5.4 Lentigno gna Melanoma
5.5 Nodular Melanoma
5.6 Superficial Spreading Melanoma
5.7 Other Cancer Types
6 Global Melanoma Diagnostics and Therapeutics Market, By Diagnosis
6.1 Introduction
6.2 Dermatoscopy
6.3 Blood Tests
6.4 Computed Tomography (CT) Scan
6.5 Sentinel Lymph Node Biopsy
6.6 Ultrasound
6.7 X-Rays
6.8 Other Diagnosis
7 Global Melanoma Diagnostics and Therapeutics Market, By Therapy
7.1 Introduction
7.2 Chemotherapy
7.3 Biological Therapy
7.4 Immune Therapy
7.5 Radiotherapy
7.6 Targeted Therapy
7.7 Other Therapies
8 Global Melanoma Diagnostics and Therapeutics Market, By Application
8.1 Introduction
8.2 Diagnostic Centers
8.3 Hospitals
8.4 Medical Institutions
8.5 Other Applications
9 Global Melanoma Diagnostics and Therapeutics Market, By Geography
9.1 Introduction
9.2 North America
9.2.1 US
9.2.2 Canada
9.2.3 Mexico
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 Italy
9.3.4 France
9.3.5 Spain
9.3.6 Rest of Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 New Zealand
9.4.6 South Korea
9.4.7 Rest of Asia Pacific
9.5 South America
9.5.1 Argentina
9.5.2 Brazil
9.5.3 Chile
9.5.4 Rest of South America
9.6 Middle East & Africa
9.6.1 Saudi Arabia
9.6.2 UAE
9.6.3 Qatar
9.6.4 South Africa
9.6.5 Rest of Middle East & Africa
10 Key Developments
10.1 Agreements, Partnerships, Collaborations and Joint Ventures
10.2 Acquisitions & Mergers
10.3 New Product Launch
10.4 Expansions
10.5 Other Key Strategies
11 Company Profiling
11.1 Abbott Diagnostics
11.2 Agilent Technologies
11.3 Amgen, Inc.
11.4 AstraZeneca
11.5 Biomérieux SA
11.6 Bristol Myers Squibb
11.7 Caliber Imaging & Diagnostics, Inc.
11.8 Canfield Scientific, Inc.
11.9 Dermlite
11.10 DermTech
11.11 Eli Lilly and Company
11.12 Roche Holding AG
11.13 GlaxoSmithKline PLC
11.14 Merck & Co., Inc
11.15 Novartis AG
11.16 Pfizer, Inc.
11.17 Qiagen
11.18 Sanofi
List of Tables
1 Global Melanoma Diagnostics and Therapeutics Market Outlook, By Region (2021-2030) ($MN)
2 Global Melanoma Diagnostics and Therapeutics Market Outlook, By Cancer Type (2021-2030) ($MN)
3 Global Melanoma Diagnostics and Therapeutics Market Outlook, By Acral Lentiginous Melanoma (2021-2030) ($MN)
4 Global Melanoma Diagnostics and Therapeutics Market Outlook, By Amelanotic Melanoma (2021-2030) ($MN)
5 Global Melanoma Diagnostics and Therapeutics Market Outlook, By Lentigno gna Melanoma (2021-2030) ($MN)
6 Global Melanoma Diagnostics and Therapeutics Market Outlook, By Nodular Melanoma (2021-2030) ($MN)
7 Global Melanoma Diagnostics and Therapeutics Market Outlook, By Superficial Spreading Melanoma (2021-2030) ($MN)
8 Global Melanoma Diagnostics and Therapeutics Market Outlook, By Other Cancer Types (2021-2030) ($MN)
9 Global Melanoma Diagnostics and Therapeutics Market Outlook, By Diagnosis (2021-2030) ($MN)
10 Global Melanoma Diagnostics and Therapeutics Market Outlook, By Dermatoscopy (2021-2030) ($MN)
11 Global Melanoma Diagnostics and Therapeutics Market Outlook, By Blood Tests (2021-2030) ($MN)
12 Global Melanoma Diagnostics and Therapeutics Market Outlook, By Computed Tomography (CT) Scan (2021-2030) ($MN)
13 Global Melanoma Diagnostics and Therapeutics Market Outlook, By Sentinel Lymph Node Biopsy (2021-2030) ($MN)
14 Global Melanoma Diagnostics and Therapeutics Market Outlook, By Ultrasound (2021-2030) ($MN)
15 Global Melanoma Diagnostics and Therapeutics Market Outlook, By X-Rays (2021-2030) ($MN)
16 Global Melanoma Diagnostics and Therapeutics Market Outlook, By Other Diagnosis (2021-2030) ($MN)
17 Global Melanoma Diagnostics and Therapeutics Market Outlook, By Therapy (2021-2030) ($MN)
18 Global Melanoma Diagnostics and Therapeutics Market Outlook, By Chemotherapy (2021-2030) ($MN)
19 Global Melanoma Diagnostics and Therapeutics Market Outlook, By Biological Therapy (2021-2030) ($MN)
20 Global Melanoma Diagnostics and Therapeutics Market Outlook, By Immune Therapy (2021-2030) ($MN)
21 Global Melanoma Diagnostics and Therapeutics Market Outlook, By Radiotherapy (2021-2030) ($MN)
22 Global Melanoma Diagnostics and Therapeutics Market Outlook, By Targeted Therapy (2021-2030) ($MN)
23 Global Melanoma Diagnostics and Therapeutics Market Outlook, By Other Therapies (2021-2030) ($MN)
24 Global Melanoma Diagnostics and Therapeutics Market Outlook, By Application (2021-2030) ($MN)
25 Global Melanoma Diagnostics and Therapeutics Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
26 Global Melanoma Diagnostics and Therapeutics Market Outlook, By Hospitals (2021-2030) ($MN)
27 Global Melanoma Diagnostics and Therapeutics Market Outlook, By Medical Institutions (2021-2030) ($MN)
28 Global Melanoma Diagnostics and Therapeutics Market Outlook, By Other Applications (2021-2030) ($MN)
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.
List of Figures
RESEARCH METHODOLOGY
We at ‘Stratistics’ opt for an extensive research approach which involves data mining, data validation, and data analysis. The various research sources include in-house repository, secondary research, competitor’s sources, social media research, client internal data, and primary research.
Our team of analysts prefers the most reliable and authenticated data sources in order to perform the comprehensive literature search. With access to most of the authenticated data bases our team highly considers the best mix of information through various sources to obtain extensive and accurate analysis.
Each report takes an average time of a month and a team of 4 industry analysts. The time may vary depending on the scope and data availability of the desired market report. The various parameters used in the market assessment are standardized in order to enhance the data accuracy.
Data Mining
The data is collected from several authenticated, reliable, paid and unpaid sources and is filtered depending on the scope & objective of the research. Our reports repository acts as an added advantage in this procedure. Data gathering from the raw material suppliers, distributors and the manufacturers is performed on a regular basis, this helps in the comprehensive understanding of the products value chain. Apart from the above mentioned sources the data is also collected from the industry consultants to ensure the objective of the study is in the right direction.
Market trends such as technological advancements, regulatory affairs, market dynamics (Drivers, Restraints, Opportunities and Challenges) are obtained from scientific journals, market related national & international associations and organizations.
Data Analysis
From the data that is collected depending on the scope & objective of the research the data is subjected for the analysis. The critical steps that we follow for the data analysis include:
- Product Lifecycle Analysis
- Competitor analysis
- Risk analysis
- Porters Analysis
- PESTEL Analysis
- SWOT Analysis
The data engineering is performed by the core industry experts considering both the Marketing Mix Modeling and the Demand Forecasting. The marketing mix modeling makes use of multiple-regression techniques to predict the optimal mix of marketing variables. Regression factor is based on a number of variables and how they relate to an outcome such as sales or profits.
Data Validation
The data validation is performed by the exhaustive primary research from the expert interviews. This includes telephonic interviews, focus groups, face to face interviews, and questionnaires to validate our research from all aspects. The industry experts we approach come from the leading firms, involved in the supply chain ranging from the suppliers, distributors to the manufacturers and consumers so as to ensure an unbiased analysis.
We are in touch with more than 15,000 industry experts with the right mix of consultants, CEO's, presidents, vice presidents, managers, experts from both supply side and demand side, executives and so on.
The data validation involves the primary research from the industry experts belonging to:
- Leading Companies
- Suppliers & Distributors
- Manufacturers
- Consumers
- Industry/Strategic Consultants
Apart from the data validation the primary research also helps in performing the fill gap research, i.e. providing solutions for the unmet needs of the research which helps in enhancing the reports quality.
For more details about research methodology, kindly write to us at info@strategymrc.com
Frequently Asked Questions
In case of any queries regarding this report, you can contact the customer service by filing the “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
Yes, the samples are available for all the published reports. You can request them by filling the “Request Sample” option available in this page.
Yes, you can request a sample with your specific requirements. All the customized samples will be provided as per the requirement with the real data masked.
All our reports are available in Digital PDF format. In case if you require them in any other formats, such as PPT, Excel etc you can submit a request through “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
We offer a free 15% customization with every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
We have 3 different licensing options available in electronic format.
- Single User Licence: Allows one person, typically the buyer, to have access to the ordered product. The ordered product cannot be distributed to anyone else.
- 2-5 User Licence: Allows the ordered product to be shared among a maximum of 5 people within your organisation.
- Corporate License: Allows the product to be shared among all employees of your organisation regardless of their geographical location.
All our reports are typically be emailed to you as an attachment.
To order any available report you need to register on our website. The payment can be made either through CCAvenue or PayPal payments gateways which accept all international cards.
We extend our support to 6 months post sale. A post sale customization is also provided to cover your unmet needs in the report.
Request Customization
We provide a free 15% customization on every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
Note: This customization is absolutely free until it falls under the 15% bracket. If your requirement exceeds this a feasibility check will be performed. Post that, a quote will be provided along with the timelines.
WHY CHOOSE US ?
Assured Quality
Best in class reports with high standard of research integrity
24X7 Research Support
Continuous support to ensure the best customer experience.
Free Customization
Adding more values to your product of interest.
Safe & Secure Access
Providing a secured environment for all online transactions.
Trusted by 600+ Brands
Serving the most reputed brands across the world.
